表紙:世界のアレルギー診断市場:成長、動向および予測
市場調査レポート
商品コード
603201

世界のアレルギー診断市場:成長、動向および予測

Allergy Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 113 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.12円
世界のアレルギー診断市場:成長、動向および予測
出版日: 2021年05月13日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 113 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

アレルギー診断は、様々なアレルギーの診断やモニタリング、および治療のために実施されるテストです。米国のCDC(疾病管理予防センター)によると、2012年に子供のうち、呼吸器アレルギー患者が780万人、食物アレルギー患者が410万人、皮膚アレルギー患者が880万人と報告されています。世界的に同様の傾向が見られ、その中でも特にアジア地域では患者数が多くなっています。環境汚染の拡大や、高齢化の進行、生活様式の変化、生活習慣病の増加などが当市場の成長促進要因となっています。

当レポートでは、世界のアレルギー診断市場について調査し、市場の概要、アレルゲンタイプ・製品・エンドユーザー別・地域別の市場動向、市場規模の推移と予測、市場成長要因ならびに課題の分析、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • レポートの説明
  • 調査方法
  • ステークホルダー

第2章 エグゼクティブサマリー

  • 主な所見
  • 市場概況

第3章 市場の概要

  • 市場の定義
  • 市場成長要因
    • 増加するアレルギー疾患
    • 環境汚染
    • 生活習慣病の増加
    • 高齢者の増加
    • 医療投資の増加
  • パイプライン - 現在開発中の製品
  • 市場の課題
    • 規制政策
    • 巨大な投資

第4章 世界のアレルギー診断市場:市場区分

  • アレルゲンタイプ別
    • 吸入アレルゲン
    • 食物アレルゲン
    • その他のアレルゲン
  • 製品別
    • アッセイキット
    • 機器
    • 消耗品
    • ルミノメーター
  • エンドユーザー別
    • 診断ラボ
    • 病院
    • 学術機関
    • その他

第5章 世界のアレルギー診断市場:地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
  • アジア
    • インド
    • 中国
    • 日本
    • 韓国
  • その他の地域

第6章 競合情勢

  • イントロダクション
  • 合併・買収
  • 事業拡張
  • 新製品の発売
  • 事業提携

第7章 主要企業のプロファイル

  • Biomerieux
  • Omega Diagnostics
  • Hitachi Chemical Diagnostics
  • Danaher Corporation
  • Hob Biotech group
  • Hycor Biomedical
  • Stallergenes
  • SiemensHealthcare
  • Thermo Fisher Scientific
  • Allercheck Inc.
  • Lincoln Diagnostic
  • Hob Biotech Group

第8章 付録

目次
Product Code: 52030

The Allergy Diagnostics Market is expected to register a CAGR of 11.3% during the forecast period.

Several research studies found that patients with asthma are at a higher risk for viral infections such as COVID-19 which is caused by severe acute respiratory syndrome coronavirus 2 and infect the lower and upper airway tract, thus creating a higher clinical issue in asthmatic patients.

Furthermore, according to a research study by Vincenzo Patella et al., published in Clinical and Molecular Allergy October 2020, in Italy, during the COVID-19 pandemic 2020, doctors experienced difficulties in treating chronic diseases for most patients. Moreover, most allergy/immunology care was delayed or postponed, or handled through virtual care, and for patients with asthma of a certain severity, there was a limited need for face-to-face visits under such conditions.

Allergic rhinitis or hay fever is a global health problem that is characterized by symptoms that include itching, nasal congestion, sneezing, and rhinorrhea. According to a research study by Desiderio Passali et al., published in Asia Pacific Allergy Journal January 2018, globally, the prevalence of allergic rhinitis was found to be 15%-25%. Children, adolescents, young adults were more affected by allergic rhinitis with comorbidities of asthma, sinusitis, conjunctivitis, and nasal polyposis.

Food allergy is a growing health concern, with increasing prevalence in Western countries and also in developing countries. According to a research study by Wenyin Loh et al., published in the International Journal of Environmental Research and Public Health September 2018, in Western countries, food allergy has been reported to be as high as 10%, with the greatest prevalence among younger children. Moreover, there is an increasing prevalence of food allergy in developing countries and in China and Africa reported to be similar to that of Western countries.

Therefore, with the growing burden of allergic diseases, the new diagnostic market for the same is expected to grow at a significant pace. Furthermore, the latest diagnostic strategies for allergies and researches on new approaches for treatment are expected to drive the market studied over the forecast period. However, lack of awareness about allergic diseases and affordability of allergy diagnostics is expected to restrain the market growth.

Key Market Trends

Inhaled Allergens Segment is Expected to Hold Major Market Share Over the Forecast Period

Allergens are of various types, such as consumed, ingested, contact, and inhaled. Of these, the inhaled allergens hold the largest share, as it is the most common among all the allergens.

Globally, viral infection is a major triggering factor of allergic diseases and asthma. Worldwide, the COVID-19 has challenged healthcare system capacities and reshaping doctor-patient interaction with telemedicine. According to a research study by Adriana Izquierdo-Dominguez et al., published in Current Allergy and Asthma Reports February 2021, the outbreak of COVID-19 in 2020, made it difficult to prioritize patients with allergies diseases (AD), face-to-face evaluation, and moreover concern about the possible COVID-19 diagnosis, since COVID-19 shared many symptoms in common with allergies diseases (AD).

Inhaled allergens affect the body when they come in contact with the membranes of the nostrils or throat or lungs. Pollen is the most common inhaled allergen. Ingested allergens are present in certain foods, such as soy, peanuts, and seafood.

Some of the most common symptoms of allergy, due to inhaled allergens, are itchy eyes, sneezing, watery eyes, etc. The rising pollution in the environment, coupled with the changing lifestyle of the people, is boosting the segment's growth.

The University of South Carolina, working on several inhaled allergens. For instance, it is conducted a study on dust mite allergens, which are believed to be among the most potent triggers of asthma. Most mite allergic patients (80%) have IgE antibodies against the mite allergens. These allergens are cysteine proteases and their proteolytic activity contributes significantly to allergenicity.

The market players are adopting various strategies such as product launches, collaborations, acquisitions, and expansions to increase market share. For instance, in December 2018, Hycor Biomedical Inc. received United States Food and Drug Administration (FDA) 510(k) clearance for its new allergy testing system, NOVEOS.

On the other hand, food allergens still remain to exhibit the fastest growth rate, owing to the unawareness among the individuals regarding certain food allergies, thereby, propelling the market growth.

North America Dominates the Market and is Expected to do the Same over the Forecast Period

Some of the factors that are driving the market growth include increasing incidences of allergic diseases, environmental pollution, and the presence of key market players in the region.

In the North American region, there was a huge impact of COVID-19 on allergist practices such as diagnosis of allergy diseases and have adapted to state-wide limitations in non-essential medical visits and testing and to the mitigation of the risk of disease transmission to providers, staff, and patients. Moreover, the Centers for Disease Control and Prevention (CDC) has issued many guidelines for healthcare providers, which include the use of appropriate personal protective equipment (PPE) and the evaluation and testing of patients suspected of being infected with COVID-19. It has become more important than ever to recognize the differences between allergies, infection with COVID-19, and other common upper respiratory diseases.

Asthma is a major public health concern in Canada. As a lifelong respiratory illness, asthma affects the work productivity, quality of life, mental health, and psychological wellbeing of the Canadian population. In Canada, over 3.8 million individuals had asthma in 2019, as per asthma Canada's 2019 annual asthma survey report. Due to the high incidence of asthma in Canada, it is expected to increase demand for allergy diagnostics procedures in near future.

Moreover, as per the Global Asthma Network 2018 report, the economic burden of asthma has been increased in the United States i.e., total annual asthma costs in the United States increased from USD 60 billion in 2002 to USD 64 billion in 2011. In 2018, annual direct costs per patient in the United States were more than USD 3,000. Due to high death rates associated with asthma and increasing investment in asthma in this country the market is expected to show significant growth in the future.

According to a research study by Segura, L. R., et al., published in International Nut and Dried Fruit Council 2020, the overall positivity of food allergy to at least one food among the Brazilian population was 24%. Moreover, positivity for foods was more frequent across different age groups in young children (less than 5 years) with milk, and in older children (6-17 years) food allergy was shown with peanut, almond, wheat, soy, and maize.

There are several factors that make the United States the largest market for allergy diagnostics, such as high awareness toward allergies among the population, better regulatory guidelines that mandate allergic testing in all cases of intensive and emergency care, and better healthcare infrastructure to deal with patient's allergic situations. Thus, considering above mentioned factors it is expected to fuel the market growth in the North American region over the forecast period.

Competitive Landscape

The Allergy Diagnostics Market is fragmented, competitive, and consists of several market players. The presence of major market players, such as BioMerieux SA, Thermo Fischer Scientific Inc, Omega Diagnostics, Siemens Healthineers AG, Hitachi Chemical Diagnostics Inc., and Danaher Corporation, is intensifying the market competition. The increasing innovation and rise in investment for various public and private organizations are expected to intensify the industry rivalry across the world.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidences of Allergic Diseases
    • 4.2.2 Environmental Pollution
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness About Allergic Diseases
    • 4.3.2 Affordability of Allergy Diagnostics
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Allergen
    • 5.1.1 Inhaled Allergens
    • 5.1.2 Food Allergens
    • 5.1.3 Other Allergens
  • 5.2 By Product
    • 5.2.1 Instruments
    • 5.2.2 Consumables
    • 5.2.3 Luminometers
  • 5.3 By End User
    • 5.3.1 Diagnostic Laboratories
    • 5.3.2 Hospitals
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 BioMerieux SA
    • 6.1.2 Danaher Corporation
    • 6.1.3 Showa Denko Materials Co., Ltd. (Hitachi Chemical Diagnostics)
    • 6.1.4 HOB Biotech Group Corp. Ltd
    • 6.1.5 HYCOR Biomedical
    • 6.1.6 Lincoln Diagnostics Inc.
    • 6.1.7 Omega Diagnostics Group Plc
    • 6.1.8 Siemens Healthineers AG
    • 6.1.9 Stallergenes Greer Ltd
    • 6.1.10 Thermo Fischer Scientific Inc
    • 6.1.11 PerkinElmer Inc. (Euroimmun AG )
    • 6.1.12 R-Biopharm AG
    • 6.1.13 Immunodiagnostic Systems Holdings PLC (IDS)
    • 6.1.14 Biomerica, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS